Actively Recruiting

Age: 18Years +
All Genders
ID06305728

Immuno-Positron Emission Tomography and Hyperpolarized C Pyruvate MRI with Blood Biomarkers for Early Detection of Pancreatic Adenocarcinoma in High-Risk Pancreatic Cystic Neoplasms

Led by Memorial Sloan Kettering Cancer Center · Updated on 2025-10-09

25

Participants Needed

8

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are studying ways to detect pancreatic ductal adenocarcinoma (PDAC) early in patients with pancreatic cysts to avoid invasive surgery. They believe that combining special imaging techniques with blood tests may help identify PDAC at an early stage. This observational study focuses on patients with high-risk pancreatic cystic neoplasms who require surgical removal. Participants may undergo an ImmunoPET scan using the imaging agent 89Zr-DFO-HuMab-5B1 and a hyperpolarized pyruvate magnetic resonance imaging (HP MRI) scan before surgery. Blood samples will be collected within six weeks before surgery and then annually after surgery as part of post-operative care. These tests are being evaluated to find the best combination for detecting PDAC early. During the study, participants will have imaging scans and blood tests to monitor their pancreatic cysts. Researchers will assess the sensitivity of the ImmunoPET scan to detect the presence or absence of adenocarcinoma over one year. The study includes monitoring of liver, kidney, and heart functions to ensure participant safety. The total duration and follow-up depend on the participant's surgery and post-operative care schedule.

CONDITIONS

Brief Title

Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Men and women aged over 18 years
  • Diagnosed with a pancreatic cystic neoplasm considered high risk and requiring surgical removal
  • Able to provide informed consent
Not Eligible

You will not qualify if you...

  • Pathologic evidence of pancreatic cancer
  • Pregnant or breastfeeding patients
  • Unable or unwilling to tolerate scans due to anxiety or claustrophobia
  • Unable to lie flat or meet standard MRI requirements
  • Liver function tests outside normal limits within 6 weeks before enrollment (Bilirubin > 1.5 x ULN, AST/ALT > 2.5 x ULN, Albumin < 3 g/dL, GGT > 2.5 x ULN if Alkaline Phosphatase > 2.5 x ULN)
  • Kidney function impaired with Creatinine > 1.5 x ULN or creatinine clearance less than 60 mL/min within 6 weeks before enrollment
  • Heart conditions including congestive heart failure with NYHA class 2 or higher, poorly controlled hypertension, recent significant EKG abnormalities, or heart attack within 6 months before enrollment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - Up to 6 weeks before surgery

Participants who choose to will undergo immunoPET and HP MRI scans before surgery to detect pancreatic adenocarcinoma.

1 to 2 visits depending on participant choice

Surgery and Immediate Post-operative Care

Duration - Day of surgery

Participants undergo surgical removal of the high-risk pancreatic cystic neoplasm.

1 in-person visit for surgery

Post-operative Follow-up

Duration - Up to 1 year post surgery

Participants have blood assays drawn within 6 weeks of surgery and annually as part of post-operative care.

1 visit within 6 weeks after surgery and annual visits thereafter

Trial Site Locations

Total: 8 locations

1

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, United States, 07920

Actively Recruiting

2

Memorial Sloan Kettering Monmouth (Limited protocol activities)

Middletown, New Jersey, United States, 07748

Actively Recruiting

3

Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, United States, 07645

Actively Recruiting

4

Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity)

Commack, New York, United States, 11725

Actively Recruiting

5

Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, United States, 10604

Actively Recruiting

6

Memorial Sloan Kettering Cancer Center (All protocol activites)

New York, New York, United States, 10065

Actively Recruiting

7

Weill Cornell Medical Center (Specimen Analysis Only)

New York, New York, United States, 10065

Not Yet Recruiting

8

Memorial Sloan Kettering Nassau (Limited Protocol Activites)

Rockville Centre, New York, United States, 11553

Actively Recruiting

Loading map...

Research Team

K

Kevin Soares, MD

D

David Kelson, MD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

Development of Biomarkers for the Early Detection, Surveilla...

Pancreatic Cancer

Actively Recruiting

13 locations

Artificial Intelligence in Endoscopic Ultrasound to Detect P...

Pancreatic Cancer

Actively Recruiting

1 location

Bio-Repository of High Risk Cohorts for the Early Detection ...

Pancreatic Cyst

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here